*Guest Article by Marcello Patané, Founder and Principal, Common Synapse. If you would like to submit an article or blog post please email [email protected].
The standard account of optic neuritis runs in three steps: vision deteriorates, the acute episode passes, and sight recovers. For a biotech developing a therapy, the word recovery needs a definition. Does it mean that vision improved on a clinical measure, or that someone can rely on their vision again in ordinary life? Patients often describe more than the clinical measures show.
Patients describe the difference in their own words.
"…
More than 1.5 billion people worldwide carry elevated Lp(a) levels, a genetically determined cardiovascular risk factor for which no approved treatment exists. This combination of massive prevalence, robust causal evidence and an active therapeutic pipeline, makes Lp(a) research on of the most dynamic and operationally demanding areas for CROs in the coming decade.
Read the article by Javier Ortega, Senior Medical Manager – Pivotal
If you would like to submit a guest blog please email [email protected].
Sponsored by Pharmagene Discovery Services
Presenting:
Selected by a panel of international life science industry commentators these companies have been shortlisted in the Best Pre-Clinical R&D Stage Company of the Year and will be presenting in the Company Showcase Stream at Genesis on 10 December 2026 in London.
They are at the cutting edge of biotech, spanning AI-driven drug discovery, longevity science, next-generation antibody therapeutics, and specialised paediatric oncology treatment.
Axiom Therapeutics
The Core Innovation: A London-based techbio company that…
There is often a distinction drawn between ‘Creative Industries’ and ‘Science and Technology Industries’ when describing economic development, career options and individual identities. The definition of creative industries that is often used is ‘economic sectors that originate from individual creativity, skill, and talent, generating wealth and jobs through the creation and exploitation of intellectual property.’ A definition that if one considers the individual insight, skill, talent and creativity that leads to the invention and design of a new medicine, could be equally applied…
Over recent months One Nucleus has consulted widely on the why, what, and who aspects of choosing the right events to attend to balance cost, approaches, and expectations to meet the business needs most cost-effectively.
by Tony Jones, CEO, One Nucleus
In this article:
Why are you attending that event?
Good practice guide for event selection, preparedness and presence
One Nucleus lessons and changes
There has never been a time when human nature hasn’t driven most to want to be more efficient. Without this, bio-partnering platforms, business intelligence databases and investment…
*Guest Article by Laura Murray, Head of Business Development, Cellular and Molecular Therapies, NHS Blood and Transplant (NHSBT). If you would like to submit an article or blog post please email [email protected].
Cell and gene therapies have moved beyond scientific promise to clinical reality. Patients with cancer, rare diseases and inherited disorders are now receiving treatments that would have seemed unimaginable just a decade ago. Yet alongside these advances sits a persistent challenge: many therapies are just too costly to deliver,
Good Manufacturing Practice (GMP) is often blamed…
by Alicia Gailliez, Business Development Manager, One Nucleus
ON Helix has always been a place that brings the life science community together to create conversation on the emerging trends, technologies and ideas that are shaping the translational research landscape. It is an opportunity to learn about where the sector is heading, what this means for your organisation and how these new approaches could shape the way we work and ultimately improve outcomes for patients. It is also a place to build relationships across the ecosystem, exchange knowledge and ideas, and create new collaborations…
*Guest article by LimestoneGrey. If you would like to submit an article or blog post please email [email protected].
The number of R&D tax relief claims has fallen, but HMRC’s latest statistics paint a much more positive picture of the R&D behind them.
HMRC estimates that 40,325 R&D tax relief claims were made for the 2024/25 financial year, 17% fewer than the previous year. Yet the amount of qualifying R&D expenditure underpinning claims increased by 7% to £51 billion, while the total value of relief claimed increased by 5% to £8.2 billion.
For R&D-intensive sectors…
by Philippa Clark, Director of Business Development, One Nucleus
Spend any time around fundraising and you'll quickly notice how much attention is given to the pitch. Founders are encouraged to refine their story, perfect their deck and rehearse their delivery. It's sensible advice, but I increasingly find myself questioning whether we place too much emphasis on the moment an investor enters the room and not enough on everything that happens beforehand.
Because whilst investment may progress with a pitch, it rarely starts or finishes there.
Over the years, I've had the…
*Guest article recommendation from Cellvanta Ltd. If you would like to submit an article or blog post please email [email protected].
This recent article by Siddharth Krishnan, Director and Principal Consultant at Cellvanta Ltd in Cell&Gene discusses the recurring challenge of demonstrating process and analytical comparability in cell and gene therapy development. Comparability is often treated as a problem that begins when a manufacturing or analytical change occurs. The article introduces “comparability debt” to describe the technical uncertainty that can accumulate earlier, when…